Mesoblast reports Q1 Ryoncil gross revenue $13.2M

Mesoblast (MESO) announced gross revenue from sales of Ryoncil through the first quarter post product launch. Ryoncil is the first and only FDA approved mesenchymal stromal cell product in the Unites States and became commercially available for purchase on March 28, 2025, within one quarter of receiving FDA approval for treatment of steroid-refractory acute graft-versus-host disease in children. Mesoblast Chief Executive Dr. Silviu Itescu said, “We are pleased with the commercial launch activities of Ryoncil in the first quarter post-launch and look forward to updating on the current quarter’s progress now that mandatory state CMS coverage has become effective as of July 1, and we complete onboarding of the remaining major U.S. transplant centers.”